InsiderPulse
Dashboard

DYN

Dyne Therapeutics, Inc.

Health CareRussell 2000

Dyne Therapeutics, Inc. insider trading

Dyne Therapeutics, Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in Waltham, MA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent DYN insider transactions

6 insiders traded DYN on the open market between Jul 07, 2026 and Sep 08, 2026 — 24 sales worth $79.2M, of which every one was pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$79.2M

24 of 24 on a 10b5-1 plan

Net
−$79.2M
Insiders
6

Open-market purchases (code P) and sales (code S) from Dyne Therapeutics, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every DYN Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

DYN insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 13 insiders traded DYN on the open market: 10 purchases worth $1.5M and 210 sales worth $182.7M, 195 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 8 purchases ($1.2M) and 100 sales ($78.5M), by 7 insiders.

QuarterBoughtSold
Q2 2026+$156.8K4 buys−$62.6M84 sales · 83 on a plan
Q1 2026+$118K3 buys−$15.7M8 sales · all on a plan
Q4 2025—−$76.4K3 sales · all on a plan
Q3 2025+$911K1 buy−$108K5 sales · all on a plan
Q2 2025—−$74.1K3 sales · all on a plan
Q1 2025—−$200.2K9 sales · all on a plan
Q4 2024—−$15.8M25 sales · 13 on a plan
Q3 2024+$264.3K2 buys−$88.1M73 sales · 71 on a plan
Largest purchase
+$911K of DYN by Cox John (CEO & President · Director) on Jul 14, 2025.
Largest sale
−$5.9M of DYN by Kersten Dirk (Director) on Aug 15, 2024, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Rhodes Jason P10b5-1

    Director

    −$2.2M

    Jun 29, 2026

    102,969 sh · $21.14

  • Rhodes Jason P10b5-1

    Director

    −$1.1M

    Jun 29, 2026

    51,756 sh · $21.14

  • Rhodes Jason P10b5-1

    Director

    −$860.4K

    Jun 29, 2026

    40,702 sh · $21.14

  • Rhodes Jason P10b5-1

    Director

    −$3.5M

    Jun 26, 2026

    162,954 sh · $21.28

  • Rhodes Jason P10b5-1

    Director

    −$1.7M

    Jun 26, 2026

    81,903 sh · $21.28

  • Rhodes Jason P10b5-1

    Director

    −$1.4M

    Jun 26, 2026

    64,411 sh · $21.28

  • Rhodes Jason P10b5-1

    Director

    −$267.9K

    Jun 25, 2026

    12,699 sh · $21.10

  • Rhodes Jason P10b5-1

    Director

    −$134.7K

    Jun 25, 2026

    6,382 sh · $21.10

  • Rhodes Jason P10b5-1

    Director

    −$105.9K

    Jun 25, 2026

    5,019 sh · $21.10

  • Lucera Erick

    Chief Financial Officer

    −$48.1K

    Jun 25, 2026

    2,362 sh · $20.37

  • Rhodes Jason P10b5-1

    Director

    −$1.1M

    Jun 24, 2026

    50,530 sh · $21.02

  • Rhodes Jason P10b5-1

    Director

    −$533.8K

    Jun 24, 2026

    25,397 sh · $21.02

  • Rhodes Jason P10b5-1

    Director

    −$419.8K

    Jun 24, 2026

    19,973 sh · $21.02

  • Rhodes Jason P10b5-1

    Director

    −$1.6M

    Jun 23, 2026

    77,855 sh · $21.13

  • Kersten Dirk10b5-1

    Director

    −$1.5M

    Jun 23, 2026

    71,629 sh · $21.04

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Dyne Therapeutics, Inc. company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
Waltham, MA
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001818794

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought DYN

What the stock actually did in the 90 days following each open-market purchase

Don't check DYN — let it ping you

Get told the moment an insider moves on DYN

Pro watches Dyne Therapeutics, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add DYN to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track DYN on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read DYN insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

IMVTINSMIOVAITCIKYMRLEGNMDGLMRUSNUVLPCVXPTGXRVMD
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are DYN insiders buying or selling?
Between Jul 07, 2026 and Sep 08, 2026, 6 Dyne Therapeutics, Inc. insiders made no open-market purchases and 24 sales worth $79.2M, a net sale of $79.2M. 24 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much DYN stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 13 Dyne Therapeutics, Inc. insiders made 10 open-market purchases worth $1.5M and 210 sales worth $182.7M. 195 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: 8 purchases ($1.2M) and 100 sales ($78.5M). The largest purchase was Cox John buying $911K on Jul 14, 2025. The largest sale was Kersten Dirk selling $5.9M on Aug 15, 2024.
What was the largest recent DYN insider trade?
Rhodes Jason P (Director) sold $34M of DYN stock on Aug 14, 2026 at about $25.00 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy DYN shares?
No open-market purchase by a Dyne Therapeutics, Inc. insider appears in the filings from Jul 07, 2026 to Sep 08, 2026 — every recorded open-market transaction in that period was a sale. Before that, the most recent purchase in SEC's data was Posner Brian S buying $33.9K on Jun 08, 2026.
Where does DYN insider trading data come from?
From the Form 4 filings Dyne Therapeutics, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.